News & Events
Read articles from the MassGeneral Institute for Neurodegenerative Disease (MIND) annual Research Reviews, plus articles from the MGH Hotline, Mass General Magazine, and Mass General Public Affairs.
11/1/17 - Mass General researchers advance understanding of Parkinson’s disease in their search for a cure.
11/1/17 - Mass General researchers like Ghazaleh Sadri-Vakili, PhD, are pursuing new genetic advances that offer hope for Huntington’s disease treatments.
11/1/17 - By creating Alzheimer’s in a dish, Mass General researchers have identified dozens of promising drugs that could help slow the disease’s progress.
11/1/17 - Mass General researchers are exploring the genetic mechanisms of ALS in their quest to develop effective treatments.
8/28/17 - Read the full story here.
6/22/2017 - Read the full story here.
Saturday, June 10, 2017 - MassGeneral Institute for Neurodegenerative Disease, Charlestown Navy Yard, 114 16th Street, Boston, Massachusetts 02129. Registration is free. Please call (617) 643-0654. Learn more.
4/5/2017 - Read the full story and watch the video here.
3/3/2017 - Read the full story here.
3/02/17 - Watch the video.
1/23/17 - Read the full story here.
12/21/2016 - Read the full article here.
11/15/2016 - Read the full article here.
SPECIAL MIND SEMINAR
MassGeneral Institute for Neurodegenerative Disease
"Organs-on-Chips Technology: A Human-Relevant Platform for Disease Modeling and Precision Medicine"
9/06/2016 - Read the full article here.
7/29/2016 - Read the full article here.
5/26/2016 - Read the full story here.
4/20/2016 - Read the full article here.
03/22/2016 - Read the full story here.
03/17/2016 - Read the full story here.
03/08/2016 - Read the full story here.
03/04/2016 - Read the full story here.
2/29/2016 - Read the full story here.
1/02/16 - Read the full article here.
12/28/15 - Read the full article here.
12/23/2015 - Read the full article here.
12/02/2015 - Read the full article here.
8/Oct/2015 - Read the full article here.
21/Sept/2015 - “Clearly the Ice Bucket Challenge brought a lot of attention to ALS and brought a lot of funding in to ALS but to a lot of organizations that support ALS research,” said Dr. James Berry, a neurologist and clinical researcher at Massachusetts General Hospital, who is participating in Answer ALS.
10/Sept/2015 - Read the full article here.
9/Sept/2015 - “By leveraging clinical and sample data collection systems built by the Northeast ALS Consortium (NEALS) with the support of the ALS Association and ALS Finding a Cure Foundation, enrollment of participants and sharing of data and samples will be accelerated,” said Merit Cudkowicz, MD, Chief of Neurology and Co-Director of the Neurological Clinical Research Instit
24/Aug/2015 - Read the full article here.
20/Aug/2015 - Read the full article here.
8/Aug/2015 - Read the full article here.
20/July/2015 - Read the full article here.
16/July/2015 - Read the full article here.
26/June/2015 - Read the full article here.
16/June/2015 - Read the full article here.
15/June/2015 - Learn how the Walk of Hope, sponsored by the ALS Raising Hope Foundation raises funds for neurodegenerative disease research at MIND-and how researchers are using it to find cures.
28/May/2015 - Read the full article here.
16/Apr/2015 - Dr. Rudy Tanzi has been named one of TIME Magazine's Top 100 Most Influential People. Dr.
15/Apr/2015 — The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute today announced they are collaborating with GlaxoSmithKline (GSK) on a clinical trial to ev
20/Mar/2015 The MGH Department of Neurology is pleased to welcome Laurie J. Ozelius, PhD, a research scientist specializing in gene discovery in movement disorders, in particular identifying genes for Dystonia and Parkinson Disease, as an Associate Geneticist in Neurology.
17/Feb/2015 Merit Cudkowicz, MD and Nazem Atassi, MD, MMsc, have had their ALS research, "Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28," published in NeuroImage Clinical, A Journal of Diseases affecting the Nervous System. To read the full paper, please click
23/Jan/2015 MGH Neurologist, Brian Edlow, MD, ex vivo TBI imaging research was highlighted in "The Invisible War on the Brain," in the latest issue of National Geographic. Diffusion tensor imaging tractography dramatically reveals the breakdown of neural connections in the brain of a civilian victim of severe traumatic brain injury, compared with a healthy brain.
21/Jan/2015 MGH Neurologist, Brian Edlow, MD, is the lead researcher on a team exploring coma and consciousness. His take on near death experiences are that they are most likely the result of neurological phenomena in the brain as the brain is dying. But, Dr. Edlow admits that there is very little science to explain what so many have described.
29/Oct/2014 A study led by investigators from Massachusetts General Hospital and the Perelman School of Medicine at the University of Pennsylvania has identified a potential target for therapies to treat cocaine addiction.
12/Oct/2014 An innovative laboratory culture system has succeeded, for the first time, in reproducing the full course of events underlying the development of Alzheimer’s disease.
01/Nov/2014 At its facility at MGH East in Charlestown, the Mass General Institute for NeuroDegenerative Disease (MIND) houses the world’s premier laboratories investigating neurodegenerative diseases including Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease).
12/Oct/2014 For the first time, and to the astonishment of many of their colleagues, researchers created what they call Alzheimer’s in a Dish — a petri dish with human brain cells that develop the telltale structures of Alzheimer’s disease.
12/Oct/2014 Alzheimer’s disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-β plaques and neurofibrillary tangles1. The amyloid hypothesis of Alzheimer’s disease posits that the excessive accumulation of amyloid-β peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau2, 3.
Read about research in Alzheimer’s, ALS, Huntington’s and Parkinson’s diseases at the MassGeneral Institute for Neurodegenerative Disease in the Research Reviews.
Archive of Research Review Issues:
In the MassGeneral Institute for Neurodegenerative Disease Research Review we spotlight the groundbreaking work of scientists researching Alzheimer’s, ALS, Huntington’s and Parkinson’s diseases. To view the archive, click here.
29/Aug/2014 An assay designed to measure normal and abnormal forms of the huntingtin protein – the mutated form of which causes Huntington's disease (HD) – was successful in detecting levels of the mutant protein in a large multicenter study of individuals at risk for the devastating neurological disorder.
10/Sep/2014 There are a lot of people who watch the show who have Alzheimer’s or dementia that don’t know it, because it starts sometimes 10 years before it is diagnosed. Alzheimer’s, it’s called a death in slow motion. It’s akin to having a sliver of your brain shaved off every day.
07/Feb/2014 The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease (HD) reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants.
11/Dec/2013 Rudy Tanzi, PhD, co-discovered the first three genes for familial Alzheimer’s Disease, and as Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, he has spent the past 20 years finding yet more clues to the causes of the disease.
10/Dec/2013 Neurofibrillary tangles, largely composed of tau protein, are one of the two pathological hallmarks of Alzheimer’s disease (AD), and are believed to be centrally involved in the neurodegenerative process.
31/Jan/2014 The Northeast ALS Consortium (NEALS) website is devoted to supporting clinical research of Amyotrophic Lateral Sclerosis (ALS) and other motor neuron disease (MND).
30/Jan/2014 We have had many inquiries regarding the BrainStorm Stem Cell Therapeutics Clinical Trial. BrainStorm is currently conducting a Phase IIa dose-escalating trial at the Hadassah Medical Center in Israel. We are working with BrainStorm on a planned Phase II study in the U.S. and hope to begin the trial this year.
10/Dec/2013 Reisa Sperling, MD is using neuroimaging to ask whether anti-amyloid antibody treatment can reverse Alzheimer’s disease pathology before memory loss sets in. “We are going beyond looking for evidence of preclinical Alzheimer’s disease,” Dr.
10/Dec/2013 Mark Albers, MD, PhD, is developing a set of simple but powerful tools that examine the cognitive processing of odors to screen for the very earliest stages of preclinical Alzheimer’s Disease. “Ultimately,” Albers says, “we are hoping to develop a test that would be noninvasive and cost-effective that could be given to essentially everyone over the age of 50.”
20/Nov/2013 Carrying a particular version of the gene for apolipoprotein E (APOE) is the major known genetic risk factor for the sporadic, late-onset form of Alzheimer's disease, but exactly how that variant confers increased risk has been controversial among researchers.
24/Sep/2013 Massachusetts General Hospital (MGH) researchers have identified and validated two rare gene mutations that appear to cause the common form of Alzheimer's disease (AD) that strikes after the age of 60.
10/Sep/2013 Ihn Sik Seong, PhD, is nothing if not patient. And ambitious. It’s a combination that comes in handy when trying to understand the molecular pathogenesis of Huntington’s disease, which has been Dr. Seong’s focus for over a decade.
22/Jul/2013 What do Gaucher’s disease, gout, and amyloid plaques have in common? For researchers at the MGH, each of them may shed light on the causes and treatment of Parkinson’s disease. In the scope of PD research across disciplines and institutes, “we have built a thread from the science to the therapeutics,” says Michael Schwarzschild, MD, PhD.
17/Jun/2013 Although a family history of Alzheimer's disease is a primary risk factor for the devastating neurological disorder, mutations in only three genes – the amyloid precursor protein and presenilins 1 and 2 – have been established as causative for inherited, early-onset Alzheimer's, accounting for about half of such cases.
12/Apr/2013 The Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis (ALS), received a Best Practices Award at the 2013 Bio-IT World Conference & Expo.
03/Apr/2013 The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis (ALS) – blocking production of a mutant protein that causes an inherited form of the progressive neurodegenerative disease – may be a first step towards a new era in the treatment of such disorders.
25/Apr/2013 Massachusetts General Hospital (MGH) investigators have determined that one of the recently identified genes contributing to the risk of late-onset Alzheimer's disease regulates the clearance of the toxic amyloid beta (A-beta) protein that accumulates in the brains of patients with the disease.
17/Dec/2012 A study by Massachusetts General Hospital researchers adds further support to the possibility that increasing levels of the antioxidant urate may protect against Parkinson's disease.
29/Nov/2012 Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease. The study led by Massachusetts General Hospital (MGH) researchers will appear in the Dec.
18/Oct/2012 Understanding who is most susceptible to Alzheimer's disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer's Whole Genome Sequencing (WGS) focused on families afflicted with the disease.
23/May/2012 Use of the antioxidant urate to protect against the neurodegeneration caused by Parkinson's disease appears to rely on more than urate's ability to protect against oxidative damage.